AstraZeneca has suffered a blow after a childhood asthma drug being developed by one of its collaborators failed its phase III clinical trials.MAP Pharmaceuticals, Inc. said Unit Dose Budesonide (UDB) did not work as hoped in controlling asthma either at night or during the day.
London-based AstraZeneca, which employs more than 7,000 people in Alderley Park and Macclesfield, said it would analyse the data with MAP Pharmaceuticals to decide the next step in the programme.AstraZeneca and MAP Pharmaceuticals, which is based in Mountain View, California, have a collaboration agreement to develop and commercialise UDB.
When the deal was announced in December, AstraZeneca said it was giving MAP Pharmaceuticals an upfront cash payment of $40m and an additional $35m if it passed Phase III trials.
More
No comments:
Post a Comment